Payment overview · 2025
General Payments
$536.16
24 reported records · 9 companies
Healthcare provider profile · identity verified
Karanbir Brar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · OCEANSIDE, CA · NPI 1306191473
Verified facts
What the public records show
CMS Open Payments records show Karanbir Brar, M.D. received $536.16 in general payments during 2025 across 24 reported records.
ABBVIE INC. accounted for 60.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $321.78 | 60.0% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.73 | 8.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.99 | 6.2% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $31.70 | 5.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.13 | 4.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.34 | 4.3% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $22.81 | 4.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.65 | 3.9% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.03 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $536.16 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $275.21 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $217.16 | 9 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $46.57 | 3 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $46.57 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.73 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.73 | 2 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $39.97 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.99 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $31.70 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $26.39 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $22.81 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 421 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 407 | 79 |
| Gabapentin | Gabapentin | 295 | 49 |
| Metformin Hcl | Metformin Hcl | 291 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 68 |
| Eliquis | Apixaban | 285 | 42 |
| Furosemide | Furosemide | 256 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 221 | 47 |
| Losartan Potassium | Losartan Potassium | 190 | 47 |
| Potassium Chloride | Potassium Chloride | 182 | 41 |
| Trazodone Hcl | Trazodone Hcl | 182 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 178 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 45 |
| Carvedilol | Carvedilol | 155 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 49 |
| Lisinopril | Lisinopril | 140 | 41 |
| Donepezil Hcl | Donepezil Hcl | 134 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 127 | 32 |
| Famotidine | Famotidine | 119 | 19 |
| Simvastatin | Simvastatin | 107 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 93 | 30 |
| Finasteride | Finasteride | 90 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 19 |
| Spironolactone | Spironolactone | 87 | 24 |
| Omeprazole | Omeprazole | 81 | 18 |
| Mirtazapine | Mirtazapine | 78 | 19 |
| Lactulose | Lactulose | 77 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 20 |
| Levetiracetam | Levetiracetam | 70 | 14 |
| Sertraline Hcl | Sertraline Hcl | 66 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 15 |
| Divalproex Sodium | Divalproex Sodium | 63 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 19 |
| Lorazepam | Lorazepam | 60 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 53 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 53 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 52 | suppressed |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Prednisone | Prednisone | 48 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 45 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 45 | 16 |
| Cephalexin | Cephalexin | 44 | 38 |
| Allopurinol | Allopurinol | 43 | 12 |
| Brilinta | Ticagrelor | 43 | suppressed |
| Celecoxib | Celecoxib | 43 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 43 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 43 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 28 |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Latanoprost | Latanoprost | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 13 |
| Nystatin | Nystatin | 33 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Risperidone | Risperidone | 32 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 17 |
| Sevelamer Carbonate | Sevelamer Carbonate | 31 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Briviact | Brivaracetam | 29 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Folic Acid | Folic Acid | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 21 |
| Bumetanide | Bumetanide | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Azithromycin | Azithromycin | 25 | 21 |
| Levofloxacin | Levofloxacin | 25 | 19 |
| Olanzapine | Olanzapine | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 20 |
| Valsartan | Valsartan | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Xifaxan | Rifaximin | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Scopolamine | Scopolamine | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | 14 |
| Glipizide | Glipizide | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 20 |
| Digoxin | Digoxin | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Sulfasalazine | Sulfasalazine | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | suppressed |
| Dexamethasone | Dexamethasone | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 16 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Valproic Acid | Valproic Acid | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Olanzapine Odt | Olanzapine | 14 | suppressed |
| Paliperidone Er | Paliperidone | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Entacapone | Entacapone | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | 11 |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $536.16 · 24 records | ABBVIE INC. | AUSTEDO XR, AVYCAZ, DALVANCE, EMBLAVEO, EVENITY, LifeVest, MOUNJARO, NUPLAZID, Ozempic, PROLIA, QULIPTA, Rybelsus, TEFLARO, TRELEGY ELLIPTA, UBRELVY, WATCHMAN FLX, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error